BiotechTube

AZD5634 for inhalation + AZD5634 for infusion

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Feb 11, 2016 → Oct 24, 2016

NCT ID
NCT02679729

About AZD5634 for inhalation + AZD5634 for infusion

AZD5634 for inhalation + AZD5634 for infusion is a phase 1 stage product being developed by AstraZeneca for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02679729. Target conditions include Cystic Fibrosis.

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis were approved

Approved (20) Terminated (7) Active (0)
✅CefiderocolShionogiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PancrelipaseAbbVieApproved
✅Tedizolid PO + Tedizolid IVMerckApproved
✅Alendronate + PlaceboMerckApproved
✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved
✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02679729Phase 1Completed

Competing Products

20 competing products in Cystic Fibrosis

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
36
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
Enfortumab VedotinAstellas PharmaPhase 2
42
CefiderocolShionogiApproved
43
LenvatinibEisaiPhase 2
39
Lenvatinib + PembrolizumabEisaiPhase 2
39
CREONAbbVieApproved
43
Pancrelipase + PancrelipaseAbbVieApproved
43
Creon IR + Creon® (DR/GR)AbbViePhase 2
35
ABBV-CLS-628 + PlaceboAbbViePhase 2
42
Elagolix + PlaceboAbbViePhase 2
35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
35
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
27
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
40
AZD1236 + PlaceboAstraZenecaPhase 2
27
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
36
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
35
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
35